Ketamine normalizes brain activity during emotionally valenced attentional processing in depression

Introduction

Reed and colleagues frame the study within the unmet need for faster-acting pharmacological treatments for major depressive disorder (MDD). They note that ketamine, a glutamatergic modulator, produces rapid antidepressant effects but that its precise neural mechanisms—particularly effects on cognitive and affective processing domains such as emotion processing—remain incompletely understood. Earlier behavioural work suggests that people with MDD often show a cognitive bias toward negative emotional information, and prior neuroimaging studies using dot probe tasks and other emotion paradigms have revealed group differences in brain regions including the cingulate and insula even when behavioural bias is absent. The authors point out that most previous ketamine fMRI work lacked simultaneous, longitudinal assessments of both MDD and healthy control (HC) participants and often did not include placebo controls, limiting interpretation of ketamine-specific effects on emotional processing networks. This study therefore set out to examine how a subanesthetic ketamine infusion affects brain activity during an emotionally valenced attentional dot probe task in unmedicated, treatment-resistant MDD participants and HCs. Using a randomized, double-blind, placebo-controlled crossover design with multiple fMRI time points (baseline, ~2 days post-infusion, and ~11 days post-infusion for each drug condition), the researchers hypothesised that ketamine would alter activation in regions implicated in emotional processing and depression, and that these effects might differ between MDD and HC groups. The approach was intended to test whether ketamine produces a normalising pattern of brain function during attentional-emotional processing in MDD relative to controls.